Long-term COVID has been linked to stress, depression and cognitive impairment.

Published Date: 13 Mar 2023

Canada: Long-term COVID-19 associated with psychiatric symptoms and cognitive impairment, research recently published in the journal Brain, Behavior,...

Read Full News

Latest News

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Q4 2025 Recap: Psychiatry News and Updates

Q4 2025 Recap: Psychiatry News and Updates

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Q4 2025 Recap: Psychiatry News and Updates

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

News All Time

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Q3 2025 Recap: Psychiatry News and Updates Chelsie Derman

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

I Tried to End My Life 3 Times: Today, I Help Others Fight for Theirs Diana Guzman, LMHC

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

Soft Drinks Linked to Depression Through Gut Microbiota Alterations Chelsie Derman

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Early Heart Rate Slowing Predicts Magnetic Brain Stimulation Response in MDD Chelsie Derman

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD Chelsie Derman

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Antidepressants Differ Significantly in Cardiometabolic Side Effects Chelsie Derman

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Recommended News For You

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.

Higher levels of HIF2α found to slow down aggressive childhood cancer

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

Extracellular matrix pathway emerges as treatment target for pediatric cancer

Study opens up possibility of bespoke prostate cancer treatment

Number of cancer survivors in the US reaches 18.6 million—projected to exceed 22 million by 2035

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

Recommended Articles For You

AI on the Front Lines: Revolutionizing Breast Cancer Detection with Artificial Intelligence 

A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51% 

The Growing Challenge of Haematological Malignancies in Older Adults 

Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

These Athletes Weren't Doping. Their Genes Made It Look Like They Did.

2.

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer

3.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

4.

In cancer survivors, loneliness is associated with a higher risk of death.

5.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

1.

The Importance of Maintaining Normal Calcium Levels in Your Body 

2.

Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment

3.

Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments

4.

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision

5.

Unlocking the Benefits of Eltrombopag: A Comprehensive Guide

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

2.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective

5.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot